C4X Discovery Holdings and AstraZeneca have entered into a licensing agreement to develop an oral treatment for chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory illnesses.    The companies will work to develop C4XD’s NRF2 Activator program with an initial focus on COPD. C4XD will receive $2 million upfront and is eligible for preclinical milestones of as much as $16 million, as well as another $385.8 million in clinical, commercial milestones and royalties. ...